secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124655
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen
--------------------------------------------------------------------------------

- Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.
- Preliminary I-SPY 2 EOP analysis: 95% (19/20) of patients met primary endpoint with >75% treatment completion.
- First patient dosed in combination trial of (Z)-endoxifen with abemaciclib (VERZENIO) in ER+/HER2- breast cancer.
- Ended Q3 2024 with $74.8 million cash and equivalents, no debt.
- Received new U.S. Patent No. 12,071,391 covering (Z)-endoxifen compositions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/0000950170-24-124655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer